Journal article
Global, multicenter, randomized, phase II trial of gemcitabine and gemcitabine plus AGS-1C4D4 in patients with previously untreated, metastatic pancreatic cancer †
Abstract
BACKGROUND: We evaluated AGS-1C4D4, a fully human monoclonal antibody to prostate stem cell antigen (PSCA), with gemcitabine in a randomized, phase II study of metastatic pancreatic cancer.
PATIENTS AND METHODS: Patients with Eastern Cooperative Oncology Group (ECOG) performance status 0/1 and previously untreated, metastatic pancreatic adenocarcinoma were randomly assigned 1:2 to gemcitabine (1000 mg/m(2) weekly seven times, 1 week rest, …
Authors
Wolpin BM; O'Reilly EM; Ko YJ; Blaszkowsky LS; Rarick M; Rocha-Lima CM; Ritch P; Chan E; Spratlin J; Macarulla T
Journal
Annals of Oncology, Vol. 24, No. 7, pp. 1792–1801
Publisher
Elsevier
Publication Date
7 2013
DOI
10.1093/annonc/mdt066
ISSN
0923-7534
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AdenocarcinomaAdultAgedAged, 80 and overAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntigens, NeoplasmAntineoplastic Combined Chemotherapy ProtocolsDeoxycytidineDisease-Free SurvivalFemaleGPI-Linked ProteinsHumansKaplan-Meier EstimateLiver NeoplasmsMaleMiddle AgedNeoplasm ProteinsPancreatic NeoplasmsProportional Hazards ModelsTreatment OutcomeGemcitabine